This year’s congress was held as a virtual meeting with content available online to registered participants for 12 months.
Headache could be an important predictor of the clinical course of COVID-19 in infected patients. New data on 130 patients with COVID-19 infection treated by neurologists at the Val Hebron Hospital, Barcelona, Spain, showed that those who had headache as a symptom had COVID disease for seven days less than those who did not have …
Read more »Adding CGRP monoclonal antibody (mAb) therapy to botulinum toxin can further reduce monthly headache days (MHDs) in patients with chronic migraine (CM). Results of a retrospective chart review showed that 114/153 patients (74.5%) with CM on onabotulinumtoxinA and additional CGRP mAb therapy reported a reduction in MHDs or headache pain severity. Quantitative data available on …
Read more »Erenumab reduced headaches and improved functional status in a US retrospective cohort study of adolescents with primary headache disorders (migraine, new daily persistent headache NDPH or persistent post-traumatic headache). Results of a chart review of 56 patients aged 12-17 who had failed 5-18 previous preventives are summarised in Table 1 and 2. Table 1. Efficacy …
Read more »Patients with migraine who switched from erenumab to galcanezumab reported similar headache improvement for the two drugs, according to data from a retrospective chart review at a tertiary headache centre. Between 1 May 2018 and 1 October 2019, 100 patients were switched from erenumab to galcanezumab and, at the time of review, 68 patients were …
Read more »Promising effects of anti-CGRP therapies in trigeminal neuralgia (TN) have been reported from a retrospective chart review, but the high proportion of patients who also had migraine headaches makes it difficult to draw clear conclusions. Of 23 patients, 15 met diagnostic criteria for TN (65%), six had atypical facial pain (26%) and two had post-traumatic …
Read more »Nearly 40% of patients with migraine who responded insufficiently to a triptan were able to function normally two hours after an initial dose of ubrogepant. An analysis of pooled data from the Phase 3 ACHIEVE I and II studies also showed that approximately one-third of patients were satisfied or extremely satisfied with ubrogepant and felt …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
